API
< Back to all clusters
[BUSINESS] · United States, India, Germany, United Kingdom · 2 sources

started · updated

US pharmaceutical tariff plans threaten global drug supply

The Trump administration is implementing trade policies aimed at reshaping the global pharmaceutical landscape through significant tariffs and investigations. A planned imposition of 100 per cent tariffs on imported generic medicines starting in August 2028, rising to 200 per cent after one year, seeks to incentivize companies to relocate manufacturing to the United States.

These measures pose a threat to India’s status as a primary supplier of low-cost generic drugs, which account for 90 per cent of prescriptions in the US. Analysts warn that such moves could disrupt global supply chains and impact the revenue of Indian pharmaceutical firms, which rely heavily on the US market.

Additionally, the U.S. Trade Representative has opened a Section 301 investigation into Germany regarding pharmaceutical pricing. Critics argue these trade actions, including a previous deal between the US and UK involving NHS spending on American medicines, may undermine drug affordability and impact public health outcomes globally.

Entities

Donald Trump · Germany · India · United Kingdom · United States Trade Representative